Belzutifan, A Hypoxia-Inducible Factor 2-Alpha Inhibitor, for Patients with Advanced Pheochromocytoma and Paraganglioma
Clicks: 5
ID: 324569
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
1.2
/100
5 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #324 of 373 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 373 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms arising from the sympathetic and parasympathetic nervous systems. Their heterogeneous clinical behavior and metastatic potential present significant management challenges. Pseudohypoxia driven by oxygen metabolism dysregulation is the central oncogenic mechanism in Cluster 1 PPGLs, which carry the highest metastatic risk. In these tumors, pathogenic variants in the succinate dehydrogenase complex (SDHx) or von Hippel-Lindau (VHL) gene create an intracellular environment that mimics chronic hypoxia, leading to hypoxia inducible factor 2 alpha (HIF 2α) activation and driving the hypervascularity and aggressive clinical phenotype. Belzutifan, a first in class selective HIF 2α inhibitor, has emerged as a promising therapeutic strategy for pseudohypoxia driven PPGLs. In the LITESPARK 015 phase 2 trial, belzutifan achieved a disease control rate of 85% and an overall response rate of 26% in patients with locally advanced or metastatic disease. Beyond radiographic outcomes, belzutifan provides meaningful clinical benefits, including improved blood pressure control and enhanced quality of life. Unlike cytotoxic therapies, belzutifan's safety profile is characterized by predictable, mechanism-based adverse events, most commonly grade 1-3 anemia. Belzutifan is the first oral and the second FDA-approved therapy for metastatic PPGLs establishing a new therapeutic option for these complex rare tumors. While its development underscores the utility of precision oncology, definitive molecular correlations with clinical efficacy remain to be demonstrated.
| Reference Key |
openalex_W7202128779
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Camilo Jiménez, Steven G. Waguespack, Jennifer Kaplan, Mouhammed Amir Habra, Jeena Varghese |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag324
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.